# TENT COOPERATION TREA.

То:
United States Patent and Trademark Office (Box PCT) Washington D.C. 20231 United States of America
in its capacity as elected Office
Applicant's or agent's file reference P95-20-PCT
Priority date (day/month/year) 06 April 1994 (06.04.94)
Examining Authority on:  95 (23.10.95)  ational Bureau on:
•
ate or, where Rule 32 applies, within the time limit under

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

H. Zhou

# **PCT**

PECID	2 9 APR 1996
-0	PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTIO	See Notification of Transmittal of International			
P95-20-PCT	/	Preliminary Examination Report (Form PCT/IPEA/416)			
International application No.	International filing date (	day/month/year)	Priority date (day/month/year)		
PCT/IE 95/00025 🔪	06/04/1995		06/04/1994		
International Patent Classification (IPC) or	national classification and	IPC			
	A61K9/51				
Applicant					
ELAN CORPORATION, PLC et	al.	·			
This international preliminary example Authority and is transmitted to the	nination report has been pre applicant according to Art	epared by this Inter cicle 36.	national Preliminary Examining		
2. This REPORT consists of a total	l of sheets, incl	uding this cover she	et.		
This report is also accompand been amended and are the backer (see Rule 70.16 and Section 6	isis for this report and/or st	ieets containing rect	ion, claims and/or drawings which have ifications made before this Authority e PCT).		
These annexes consists of a total of	of sheets.				
3. This report contains indications an	d corresponding pages relat	ting to the following	items:		
I X Basis of the report					
II Priority					
III Non-establishment of o	pinion with regard to nove	lty, inventive step a	nd industrial applicability		
IV Lack of unity of invent	ion				
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
VI Certain documents cite	d	•			
VII Certain defects in the i	nternational application				
	n the international applicati	on			
, Consum coss (Canonic C					
Date of submission of the demand		Date of completion	of this report		
23/10/1995 2 6. 04. 96			2 6. 04. 96		
Name and mailing address of the IPEA		Authorized officer	f c/0 CC		
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich  Authorized officer  Authorized officer  B. Merkl					
<b>O)))</b> Tel. (+49-89) 2399-0. Tx: 523656 epmu d					
Fax: (+49-89) 2399-4465	Fax: (+49-89) 2399-4465  Telephone No.				
Form PCT/IPEA/409 (cover sheet) (Januar)	y 1994) (15/1:	1/1995)			

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

I. Basis of the report	·
1. This report has been drawn up on the basis of (Replacement of the property	,
not annexed to the report since they do not contain amer	e referred to in this report as "originally filed" and are adments.):
$[\mathbf{x}]$ the international application as originally filed	
[ ] the description, pages	, as originally filed,
pages	, filed with the demand,
pages	, filed with the letter of,
pages	, filed with the letter of,
[ ] the claims, Nos.	, as originally filed,
Nos	, as amended under Article 19,
Nos	, filed with the demand,
Nos	, filed with the letter of,
Nos	, filed with the letter of,
[ ] the drawings, sheets/fig	, as originally filed,
sheets/fig	, filed with the demand,
sheets/fig	, filed with the letter of,
	, filed with the letter of
2. The amendments have resulted in the cancellation of:	
[ ] the description, pages	·
[ ] the claims, Nos	:
[ ] the drawings, sheets/fig	·
3. [ ] This report has been established as if (some of) the considered to go beyond the disclosure as filed (Ru	-
4. Additional observations, if necessary:	

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement				
1. STATEMENT				
Novelty (N)	Claims 5-16			
Inventive Step (IS)	Claims 1-16			
Industrial Applicability (IA)	Claims 1-16	·· <del>···</del>		

### 2. CITATIONS AND EXPLANATIONS

1. The following documents have been used for the purposes of this report:

D1 = EP-A-0257310

D2 = EP-A-0145240

D3 = EP-A-0330180

2. D1 discloses an effervescent drug composition comprising the active ingredient microencapsulated in cellulose polymer derivatives. Novelty of the subject-matter of present claims 1-4 cannot be acknowledded as no evidence has been submitted that the cellulose polymer used in D1 is not biodegradable in the sense of the explanation given in the present application on page 7, lines 16-20 and that the drugs cited in the bridging sentence of columns 3 and 4 of D1 do not belong to the classes of medicaments cited in present claim 1-4.

D2 (cited as X-document in the international search report) is not regarded to distroy the novelty of the

present claims as no effervescent formulation is disclosed in D2.

3. D1 is regarded to represent the closest prior art as it differs (if it differs at all, see item 2.) from the subject-matter claimed in present claim 1 only in that other drugs or another polymer is used. D1 discloses almost the same release pattern (compare figures). That means that the problem, namely to achieve a once daily formulation has already been solved by D1. It is not clear what additional problem is to be solved by the present application especially as prolonged release preparations are known from D2 and D3 comprising microcapsules the coating of which consists of biodegradable polymers such a lactic acid polymer. The dependent claims do not appear to contain any features which might render them patentable as said features are normal prcessing option for the skilled person in the field of pharmaceutical formulations.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

The requirements of Rule 5.1(a)(ii) PCT have not been met as the documents D1-D3 have not been identified in the description and the relevant background art disclosed therein has not been briefly discussed.

Claim 6 contains all features of Claim 1. Therefore it has to be drafted rather as a claim dependent on claim 1.

Claim 2 is drafted rather as a problem to be solved than the solution expressed in technical terms. The choice of an appropriate pH is obvious for the skilled person (compare e.g. D2, sentence bridging page 10 and page 11).

#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

A61K 9/51, 9/52, 9/46, 9/56, 9/58, 9/64

(11) International Publication Number:

WO 95/27482

(43) International Publication Date:

19 October 1995 (19.10.95)

(21) International Application Number:

PCT/IE95/00025

**A1** 

(22) International Filing Date:

6 April 1995 (06.04.95):

61) Designated States: AU, CA, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,

PT, SE).

(30) Priority Data:

940292

6 Àpril 1994 (06.04.94)

IE-

Published

With international search report.

(71) Applicant (for all designated States except US): ELAN COR-PORATION, PLC [IE/IE]; Monksland Industrial Estate, Athlone, County Westmeath (IE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): √FREEMAN, Virginia [IE/IE]; Tarmon, Castlerea, County Roscommon (IE). RAMTOOLA, Zebunnissa [IE/IE]; 163 Charlemont, Griffith Avenue, Dublin 9 (IE).

(74) Agent: ANNE RYAN & CO.; 60 Northumberland Road, Ballsbridge, Dublin 4 (IE).

(54) Title: EFFERVESCENT PHARMACEUTICAL FORMULATIONS CONTAINING CONTROLLED RELEASE BIODEGRADABLE **MICROCAPSULES** 

### (57) Abstract

Effervescent pharmaceutical formulations for the sustained and controlled oral administration of a drug selected from a calcium channel blocker, an ACE inhibitor, a narcotic analgesic or analogues or combinations thereof, the formulation comprising microcapsules in which the drug is entrapped in a biodegradable polymer, for example poly-L lactide. The pH of the formulation can be varied to optimize the release of the or each drug from the formulation. Microcapsules suitably have a D 50 % between about 100 nm and 900 nm and a drug loading of the order of about 10 % to 70 % by weight. The formulations can be used to administer the drugs to a patient on a once-daily basis so as to achieve a therapeutic effect over a substantially 24-hour period.



-O--- D1

**-a** -- ∪3

# INTERNATIONAL SEARCH REPORT

A CLASSIFICATION OF SUPERIOR					
A. CLASSIFICATION OF SUBJECT MATTER  A 61 K 9/51, A 61 K 9/52, A 61 K 9/46, A 61 K 9/56,  A 61 K 9/58, A 61 K 9/64					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classifi A 61 K	cation symbols)				
Documentation searched other than minimum documentation to the extent the	nat such documents are included in th	e fields searched			
Electronic data base consulted during the international search (name of data					
	tosse and, where practical, search ten	ms used)			
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claim No.			
X EP, A, 0 257 310 (BIO-DAR LTD.) 02 Ma (02.03.88), claims 1,2,4; column lines 50-56; column line 50 - column 4, line 4.	6.	1-3			
LTD.) 19 June 1985 (19.06.85),	(TAKEDA CHEMICAL INDUSTRIES, LTD.) 19 June 1985 (19.06.85), abstract; claims 1,4-6,10; page 2, lines 13-23; page 6, lines 1-12; page 7, lines 1-3; page 9, lines 10-22; page 10, line 36 -				
Further documents are listed in the continuation of box C.	Patent family members ar	e listed in annex.			
'A' document defining the general state of the art which is not considered to be of particular relevance 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed  Date of the actual completion of the international search  23 May 1995	cited to understand the princi invention  'X' document of particular releval cannot be considered novel on involve an inventive step whe  'Y' document of particular releval	nflict with the application but ple or theory underlying the nee; the claimed invention reannot be considered to note document is taken alone nee; the claimed invention we an inventive step when the ne or more other such docug obvious to a person skilled e patent family			
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Faze (+31-70) 340-16	Authorized officer  MAZZUCCO e.h	1.			

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT.					
Category *		Relevant to claim No.			
Y	page 17, lines 1-9.  EP, A, 0 330 180 (BIOMATERIALS UNIVERSE, INC.) 30 August 1989 (30.08.89), abstract; claims 1-6; page 3, line 38 - page 4, line 32; page 5, lines 36-51.	1-10, 12,13, 16			
Y	US, A, 5 178 878  (WEHLING F. et al.)  12 January 1993 (12.01.93),  claims 1,6; column 2,  lines 59-65; column 3,  lines 45-48; column 4,  lines 56-62; column 5,  lines 51-62; column 11,  lines 38-50  (cited in the application).	1-10, 12,13, 16			
` <b>Y</b>	US, A, 5 133 908 (STAINMESSE S. et al.) 28 July 1992 (28.07.92), abstract; claims 1,2,6,7; column 6, example 4; column 2, line 27 - column 3, line 18; column 3, lines 27-33; column 11, lines 42,43.	1-10, 12,13			
Y	US, A, 4 824 675  (WONG P.S.L. et al.)  25 April 1989 (25.04.89),  claims 1,4,7; fig. 2;  column 2, line 31 -  column 3, line 12;  column 12, line 38 -  column 13, line 3;  column 13, lines 30-49;  column 14, lines 38-47;  column 14, lines 64,65;  column 15, line 67 -  column 16, line 9;  column 16, line 35 -  column 17, line 46.	1-10, 12,13			
<b>A</b>	DE, A, 2 146 174  (MERCK & CO., INC.) 30 March 1972 (30.03.72), claims 1,10,11; page 2, fifth paragraph - page 4, line 3, examples 5,6; example 28.	1,3,12			

#### ANHANG

#### ANNEX

### ANNEXE

zum internationalen Recherchenbericht über die internationale Patentanmeldung Nr. to the International Search Report to the International Patent Application No.

ipport de recherche inter-cional relatif à la demande de brevet international no

### PCT/IE 95/00025 SAE 107574

In diesem Anhang sind die Mitglieder der Patentfamilien der im obenge-

This Annex lists the patent family members relating to the patent documents nannten internationalen Recherchenbericht cited in the above-mentioned interangeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unterrichtung und erfolgen ohne Gewähr.

messer Feleting to the patent document
cited in the above-mentioned international search report. The Office is
in no way liable for these particulars
which are given merely for the purpose of information.

La présente annexe indique les membres de la famille de brevets relatifs aux documents de brevets cités dans le rapport de recherche international visée ci-dessus. Les reseigne-ments fournis sont donnés à titre indicatif et n'engagent pas la responsibilité de l'Office.

de l'Office.					
angeführte Patent in sea Document	erchenbericht s Patentdokument document cited rch report de brevet cité pport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication	
EP A1	257310	02-03-88	CA A1 1312283 DE CO 3775858 EP B1 257310 JP A2 2072113 US A 4710384	05-01-93 20-02-92 08-01-92 12-03-90 01-12-87	
EF A2	145240	19-06-85	AT E 42197 CA A1 1233414 DE C0 3477732 EP A3 145240 EP B1 145240 EP B1 537325 ES A5 537325 ES A1 8605983 GR A 80818 HK A 37/92 HU B 193910 IE B 57721 JP A2 60100516 JP B4 1057087 PT A 79450 PT B 79450 PT B 79450 PT B 79450 PT B 4711782 US A 4917893 US A 5061492	15-05-89 01-03-89 24-05-89 03-07-85 19-04-89 01-05-86 01-05-86 04-03-85 17-01-92 28-11-85 28-12-93 04-03-85 04-03-85 17-01-95 28-12-89 01-12-89 01-12-84 11-12-84 11-12-84 17-01-92 24-03-87 17-01-92 29-10-91	
EP A1	330180	30-08-89	DE CO 68904326 DE T2 68904326 EP B1 330180 JF A2 1216918 US A 5100669	25-02-93 27-05-93 13-01-93 30-08-89 31-03-92	
us A	5178878	12-01-93	AU A1 66012/90 AU B2 646232 EP A1 494972 EF A4 494972 JP T2 5500956 WO A1 9104757 US A 5223264 CA AA 2061917	28-04-91 17-02-94 22-07-92 12-08-92 25-02-93 18-04-91 29-06-93	
US A	5133908	28-07-92	AT E 84710 DE CO 68904483 DE T2 68904483 EP A1 349428 EP B1 349428 ES T3 2054052 FR A2 2634397 FR B2 2634397 JP A2 2149334 JP B4 6002224 AT E 74024 CA A1 1292168 DE CO 3777796 EP A1 275796 EP B1 275796 EP B1 275796 EP B1 275796 EP B1 2608988 FR A1 2608988 FR B1 2608988 JP A2 5118528	15-02-93 04-03-93 19-05-93 03-01-90 20-01-93 01-08-94 26-01-90 19-04-91 07-06-90 12-01-94 15-04-92 19-11-91 30-04-92 27-07-88 25-03-92 01-12-92 01-07-88 11-01-91 06-10-88	

US A	4824675	25-04-89	AU A1 16517/88 AU B2 613040 CA A1 1319071 DE CO 3871273 EP A2 300623 EP A3 300623 EP B1 300623 ES T3 2031238 JP A2 1031710 US A 4915949	19-01-89 25-07-91 15-06-93 25-06-92 25-01-89 22-03-89 20-05-92 01-12-92 02-02-89 10-04-90
DE A	2146174	30-03-72	AU A1 33178/71 FR A5 2106566 FR B1 2106566 NL A 7112083	15-03-73 05-05-72 18-04-75 20-03-72

.